|
1
|
Strickler J, Nakamura Y, Shitara K, Catenacci D, Janjigian Y, Barzi A, Bekaii-Saab T, Lenz H, Lee J, Van Cutsem E, Chung H, Tabernero J, Yoshino T, Siena S, Garrido-Mayor J, Palanca-Wessels M, Xie D, Marshall J. P-174 MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
|
2
|
Horwitz S, Scarisbrick J, Prince H, Whittaker S, Duvic M, Kim Y, Quaglino P, Zinzani P, Bechter O, Eradat H, Pinter-Brown L, Akilov O, Geskin L, Sanches J, Ortiz-Romero P, Lisano J, Brown L, Palanca-Wessels M, Gautam A, Bunn V, Little M, Dummer R. FINAL DATA FROM THE PHASE 3 ALCANZA STUDY: BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN PATIENTS (PTS) WITH CD30-POSITIVE (CD30+) CUTANEOUS T-CELL LYMPHOMA (CTCL). Hematol Oncol 2019. [DOI: 10.1002/hon.96_2630] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- S.M. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York United States
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham United Kingdom
| | - H.M. Prince
- Division of Cancer Medicine; Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne; Melbourne Australia
| | - S. Whittaker
- St John's Institute of Dermatology; Guys and St Thomas NHS Foundation Trust; London United Kingdom
| | - M. Duvic
- Department of Dermatology; Division of Internal Medicine, The University of Texas MD Anderson Cancer Center; Houston United States
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford United States
| | - P. Quaglino
- Department of Medical Sciences; Dermatologic Clinic, University of Turin; Turin Italy
| | - P.L. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - O. Bechter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven KU Belgium
| | - H. Eradat
- Division of Hematology-Oncology; David Geffen School of Medicine at UCLA; Los Angeles United States
| | - L. Pinter-Brown
- Division of Hematology Oncology; Chao Family Comprehensive Cancer Center, University of California; Irvine United States
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh United States
| | - L. Geskin
- Department of Dermatology; Columbia University; New York United States
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - J. Lisano
- Medical Affairs; Seattle Genetics, Inc.; Bothell United States
| | - L. Brown
- Biostatistics; Seattle Genetics, Inc.; Bothell United States
| | | | - A. Gautam
- Global Medical Affairs; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - V. Bunn
- Oncology Statistics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge United States
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| |
Collapse
|
|
3
|
Prince H, Dummer R, Whittaker S, Horwitz S, Duvic M, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Sanches J, Ortiz-Romero P, Akilov O, Geskin L, Huen A, Wang Y, Palanca-Wessels M, Richhariya A, Feliciano J, Zhu Y, Lin H, Liu Y, Little M, Zagadailov E, Dalal M, Kim Y. PATIENT-REPORTED OUTCOMES AND QUALITY OF LIFE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: RESULTS FROM THE PHASE 3 ALCANZA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_110] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- H.M. Prince
- Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Australia
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| | - S. Whittaker
- St John's Institute of Dermatology; Guys and St Thomas NHS Foundation Trust; London UK
| | - S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham UK
| | - P. Quaglino
- Department of Medical Sciences, Dermatologic Clinic; University of Turin; Turin Italy
| | - P.L. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - P. Wolter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - L. Geskin
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - A. Huen
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - Y. Wang
- Biometrics; Seattle Genetics, Inc.; Bothell USA
| | | | - A. Richhariya
- Market Access & Health Economics; Seattle Genetics, Inc.; Bothell USA
| | - J. Feliciano
- Value and Access; Seattle Genetics, Inc.; Bothell USA
| | - Y. Zhu
- Global Statistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H. Lin
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - E. Zagadailov
- Global Outcomes Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Dalal
- Global Outcomes Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford USA
| |
Collapse
|
|
4
|
Horwitz S, Whittaker S, Duvic M, Dummer R, Kim Y, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Eradat H, Sanches J, Ortiz-Romero P, Akilov O, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Wang Y, Palanca-Wessels M, Lin H, Liu Y, Little M, Prince H. RESPONSE BY STAGE IN CD30-POSITIVE (CD30+) CUTANEOUS T CELL LYMPHOMA (CTCL) PATIENTS RECEIVING BRENTUXIMAB VEDOTIN (BV) VS PHYSICIAN'S CHOICE (PC) IN THE PHASE 3 ALCANZA STUDY. Hematol Oncol 2017. [DOI: 10.1002/hon.2438_109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Affiliation(s)
- S. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - S. Whittaker
- St John's Institute of Dermatology, Guys and St Thomas NHS Foundation Trust; London UK
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| | - Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford USA
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham UK
| | - P. Quaglino
- Department of Medical Sciences, Dermatologic Clinic; University of Turin; Turin Italy
| | - P. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - P. Wolter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - H. Eradat
- Division of Hematology-Oncology; David Geffen School of Medicine at UCLA; Los Angeles USA
| | - J. Sanches
- Department of Dermatology; University of São Paulo Medical School; São Paulo Brazil
| | - P. Ortiz-Romero
- Department of Dermatology; University Hospital 12 de Octubre, Institute i+12 Medical School, University Complutense; Madrid Spain
| | - O. Akilov
- Department of Dermatology; University of Pittsburgh; Pittsburgh USA
| | - J. Trotman
- Haematology Department, Concord Repatriation General Hospital; University of Sydney; Sydney Australia
| | - K. Taylor
- Department of Haematology, ICON Cancer Care; South Brisbane Australia
| | - S. Dalle
- Department of Dermatology, Hospices Civils de Lyon; Claude Bernard Lyon 1 University; Lyon France
| | - M. Weichenthal
- Department of Dermatology; University Hospital of Schleswig-Holstein; Kiel Germany
| | - J. Walewski
- Department of Lymphoid Malignancies; Maria Sklodowska-Curie Institute and Oncology Centre; Warsaw Poland
| | - D. Fisher
- Department of Medical Oncology; Dana-Farber Cancer Institute; Boston USA
| | - Y. Wang
- Biometrics; Seattle Genetics, Inc.; Bothell USA
| | | | - H. Lin
- Biostatistics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - Y. Liu
- Biostatistics; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H.M. Prince
- Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Australia
| |
Collapse
|
|
5
|
Kim Y, Prince H, Whittaker S, Horwitz S, Duvic M, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Bechter O, Wang Y, Palanca-Wessels M, Wood K, Li M, Liu Y, Lin H, Little M, Danaee H, Trepicchio W, Dummer R. BRENTUXIMAB VEDOTIN VS PHYSICIAN'S CHOICE IN CTCL PATIENTS FROM THE PHASE 3 ALCANZA STUDY: ANALYSIS OF OUTCOMES BY CD30 EXPRESSION. Hematol Oncol 2017. [DOI: 10.1002/hon.2437_65] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Y.H. Kim
- Department of Dermatology; Stanford University School of Medicine and Stanford Cancer Institute; Stanford USA
| | - H.M. Prince
- Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology; The University of Melbourne; Melbourne Australia
| | - S. Whittaker
- St John's Institute of Dermatology; Guys and St Thomas NHS Foundation Trust; London UK
| | - S.M. Horwitz
- Department of Medicine; Memorial Sloan Kettering Cancer Center; New York USA
| | - M. Duvic
- Department of Dermatology; The University of Texas MD Anderson Cancer Center; Houston USA
| | - J. Scarisbrick
- Department of Dermatology; University Hospital Birmingham; Birmingham UK
| | - P. Quaglino
- Department of Medical Sciences, Dermatologic Clinic; University of Turin; Turin Italy
| | - P.L. Zinzani
- Institute of Haematology; University of Bologna; Bologna Italy
| | - P. Wolter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - O. Bechter
- Department of General Medical Oncology; University Hospitals Leuven; Leuven Belgium
| | - Y. Wang
- Biometrics; Seattle Genetics, Inc.; Bothwell USA
| | | | - K.W. Wood
- Translational Medicine; Seattle Genetics, Inc.; Bothell USA
| | - M. Li
- Translational Medicine; Seattle Genetics, Inc.; Bothell USA
| | - Y. Liu
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H. Lin
- Biostatistics; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - M. Little
- Oncology Clinical Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - H. Danaee
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - W. Trepicchio
- Translational and Biomarker Research; Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; Cambridge USA
| | - R. Dummer
- Department of Dermatology; University Hospital Zürich; Zürich Switzerland
| |
Collapse
|
|
6
|
Kim Y, Whittaker S, Horwitz S, Duvic M, Dummer R, Scarisbrick J, Quaglino P, Zinzani P, Wolter P, Wang Y, Palanca-Wessels M, Zagadailov E, Trepicchio W, Lin H, Little M, Prince H. 262 Brentuximab vedotin demonstrates superior activity to standard therapy in CD30-expressing (CD30+) cutaneous T-cell lymphoma (CTCL) in the randomized phase 3 ALCANZA study. J Invest Dermatol 2017. [DOI: 10.1016/j.jid.2017.02.278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|